Diagnostics

Chung-Ang University Researchers Unveil the Biogenesis and Role of Transfer RNA Fragments in Cancer Progression

Study reveals that 5'-tRNAGly(GCC) is a key regulator of gene expression and a potential therapeutic target in cancer SEOUL, Dec.…

1 year ago

Axtria Leads Frost & Sullivan’s First Pharmaceutical Commercialization Solutions and Services Industry Radar Report

BERKELEY HEIGHTS, N.J., Dec. 12, 2024 /PRNewswire/ -- Axtria Inc., a global cloud software and data analytics company for the…

1 year ago

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

Volition to participate in the upcoming 14th Annual LifeSci Partners Corporate Access Event on January 15th, 2025 at the Beacon…

1 year ago

Myant to Reveal Award-Winning Health Platform Driven by Advanced Materials and AI at CES 2025

TORONTO, Dec. 12, 2024 /PRNewswire/ -- Myant Corp. announced it will unveil the future of human-AI interfaces at CES 2025,…

1 year ago

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient…

1 year ago

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma

AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”),…

1 year ago

Spectral AI Highlights Unprecedented Collaboration with National Leaders in Burn Care for DeepView™ System Training and Validation Studies

DALLAS, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven…

1 year ago

ProPhase Labs Secures Global Private Equity Backing, Nears Major Lozenge Deal, Adds Seasoned Industry Expert, and Plans Significant Cost-Cutting Measures

The Company will review on Thursday, December 12th, at 12:00 p.m. EST. GARDEN CITY, NY, Dec. 11, 2024 (GLOBE NEWSWIRE)…

1 year ago

Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients

Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic…

1 year ago

HMNC Brain Health Collaborates with the Austrian Institute of Technology and the Danube Private University to Win Grant from the Austrian Research Promotion Agency

Grant for "Personalized Medicine Enabled by Intelligent Sensing Systems” ProjectMUNICH, Dec. 11, 2024 (GLOBE NEWSWIRE) -- HMNC Brain Health, a…

1 year ago